Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pulmonary arterial hypertension exacerbated by ruxolitinib.

Literature DB >> 25682609

Pulmonary arterial hypertension exacerbated by ruxolitinib.

Andrew T Low¹, Luke Howard², Claire Harrison³, Robert M R Tulloh⁴.

Abstract

Entities: Chemical Disease

Keywords: JAK inhibitor; Ruxolitinib; drug induced pulmonary arterial hypertension; myelofibrosis

Mesh：

Substances：

Year: 2015 PMID： 25682609 PMCID： PMC4450640 DOI： 10.3324/haematol.2014.120816

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status.

Authors: A Cortelezzi; G Gritti; N Del Papa; M C Pasquini; R Calori; U Gianelli; M Cortiana; G Parati; F Onida; F Sozzi; C Vener; P Bianchi; G L Deliliers
Journal: Leukemia Date: 2007-09-13 Impact factor: 11.528

Review 2. Myeloproliferative disorders.

Authors: Ross L Levine; D Gary Gilliland
Journal: Blood Date: 2008-09-15 Impact factor: 22.113

3. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors: A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal: Leukemia Date: 2014-01-10 Impact factor: 11.528

Review 4. Jaks and STATs: biological implications.

Authors: W J Leonard; J J O'Shea
Journal: Annu Rev Immunol Date: 1998 Impact factor: 28.527

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

6. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors: Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal: Arthritis Rheum Date: 2011-06

Review 7. Pulmonary hypertension in patients with chronic myeloproliferative disorders.

Authors: Y Adir; M Humbert
Journal: Eur Respir J Date: 2010-06 Impact factor: 16.671

8. Role for miR-204 in human pulmonary arterial hypertension.

Authors: Audrey Courboulin; Roxane Paulin; Nellie J Giguère; Nehmé Saksouk; Tanya Perreault; Jolyane Meloche; Eric R Paquet; Sabrina Biardel; Steeve Provencher; Jacques Côté; Martin J Simard; Sébastien Bonnet
Journal: J Exp Med Date: 2011-02-14 Impact factor: 14.307

9. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

Authors: Lan Zhao; Chien-Nien Chen; Nabil Hajji; Eduardo Oliver; Emanuele Cotroneo; John Wharton; Daren Wang; Min Li; Timothy A McKinsey; Kurt R Stenmark; Martin R Wilkins
Journal: Circulation Date: 2012-06-18 Impact factor: 29.690

10. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors: Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal: Circulation Date: 2013-02-12 Impact factor: 29.690

13 in total

1. Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation.

Authors: Saadia A Faiz; Cezar Iliescu; Juan Lopez-Mattei; Bela Patel; Lara Bashoura; Uday Popat
Journal: Pulm Circ Date: 2016-12 Impact factor: 3.017

Review 2. Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors: Jason Weatherald; Laurent Savale; Marc Humbert
Journal: Curr Hypertens Rep Date: 2017-10-18 Impact factor: 5.369

3. Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension.

Authors: Salina Gairhe; Keytam S Awad; Edward J Dougherty; Gabriela A Ferreyra; Shuibang Wang; Zu-Xi Yu; Kazuyo Takeda; Cumhur Y Demirkale; Parizad Torabi-Parizi; Eric D Austin; Jason M Elinoff; Robert L Danner
Journal: Proc Natl Acad Sci U S A Date: 2021-03-16 Impact factor: 11.205

Review 4. Drug-induced pulmonary arterial hypertension: a review.

Authors: Lohit Garg; Ghulam Akbar; Sahil Agrawal; Manyoo Agarwal; Leila Khaddour; Rishin Handa; Aakash Garg; Mahek Shah; Brijesh Patel; Bhavinkumar D Dalal
Journal: Heart Fail Rev Date: 2017-05 Impact factor: 4.214

5. Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.

Authors: Orly Leiva; Siyang Ren; Donna Neuberg; Ankeet Bhatt; Andrew Jenkins; Rachel Rosovsky; Rebecca Karp Leaf; Katayoon Goodarzi; Gabriela Hobbs
Journal: Int J Hematol Date: 2022-10-02 Impact factor: 2.319

6. Prevalence of pulmonary hypertension in myelofibrosis.

Authors: Juan Lopez-Mattei; Srdan Verstovsek; Bryan Fellman; Cezar Iliescu; Karan Bhatti; Saamir A Hassan; Peter Kim; Brian A Gray; Nicolas L Palaskas; Horiana B Grosu; Mamas A Mamas; Saadia A Faiz
Journal: Ann Hematol Date: 2020-02-19 Impact factor: 4.030